Stefan Laufer

This inventor holds 22 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merckle Gmbh, Heparegenix Gmbh, C-A-I-R Biosciences Gmbh. Active years: 1999-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stefan Laufer. Retrieved from https://idiyas.com/inventor/stefan-laufer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 3)

% Patents Active = 54.5

CIPO Patents = 1

EPO Patents = 10 (Patent Applications = 11)

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 146(Granted Patents)

Location History:

Blaubeuren, DE (1999 - 2008)
Bleubeuren, DE (2009)
Tubingen, DE (2013 - 2014)
Tübingen, DE (2011 - 2024)

Company Filing History:

C-A-I-R Biosciences Gmbh

patents

Years Active: 1999-2026

Loading Chart...

Areas of Expertise:

Protein Kinase Inhibitors

Liver Regeneration

Pyrrole Derivatives

MKK4 Inhibitors

Pharmaceutical Agents

Hepatocyte Death

Imidazole Derivatives

Anti-Inflammatory Substances

Choline Salts

Dibenzocycloheptatones

Pharmaceutical Industry

Oxidative Derivatives

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643895 - Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2026-06-02),

2. 12466826 - 3-benzoyl-1H-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases (2025-11-11),

3. 12264158 - Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2025-04-01),

4. 11912701 - Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2024-02-27),

5. 11858927 - Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2024-01-02),

6. 11731968 - Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2023-08-22),

7. 11040027 - Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death (2021-06-22),

8. 8633312 - Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds (2014-01-21),

9. 8519155 - Choline and tromethamine salt of licofelone (2013-08-27),

10. 8034837 - Polymorphic form of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizin-5-ylacetic acid (2011-10-11),

11. 7582660 - 2-thio-substituted imidazole derivatives and their use in pharmaceutics (2009-09-01),

12. 7442713 - 2-thio-substituted imidazole derivatives and their use in pharmaceutics (2008-10-28),

13. 7253191 - 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry (2007-08-07),

14. 7078535 - Method for the production of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizin-5-ylacetic acid (2006-07-18),

15. 6936632 - Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof (2005-08-30),

Title: **Stefan Laufer: Innovator in Liver Regeneration**

Introduction

Stefan Laufer, a distinguished inventor based in Blaubeuren, Germany, has made significant contributions to the field of biochemistry, particularly through his innovative work on protein kinase inhibitors. With a remarkable portfolio of 19 patents, Laufer's research aims to advance therapeutic options for liver injuries and associated diseases.

Latest Patents

Among his latest innovations are compounds that function as protein kinase inhibitors, specifically targeting MKK4 (mitogen-activated protein kinase kinase 4). These compounds have been designed to promote liver regeneration and prevent hepatocyte death, crucial findings for treating liver-related issues. The invention details compounds of a specific formula that selectively inhibit MKK4 over other protein kinases, providing a focused approach to therapy. Additionally, his research has developed pyrazolo-pyridine compounds that serve a similar function, suggesting potential applications in treating osteoarthritis, rheumatoid arthritis, and CNS-related diseases.

Career Highlights

Stefan Laufer has cultivated a successful career in pharmaceutical research, holding key positions in reputable companies such as Merckle GmbH and Heparegenix GmbH. His dedication to uncovering novel therapeutic pathways has positioned him as a prominent figure in his field, contributing valuable insights that have paved the way for new treatment modalities.

Collaborations

Throughout his career, Laufer has collaborated with notable professionals, including Wolfgang Albrecht and Hans-Guenter Striegel. These partnerships have enhanced his research endeavors, fostering a collaborative spirit that drives innovation and discovery in the biochemistry landscape.

Conclusion

Stefan Laufer stands out as a pivotal inventor with a focus on advancing liver health through targeted pharmacological strategies. His extensive patent portfolio reflects his commitment to research and development, promising significant contributions to medical science and patient care in the future.

Profile summary based on public USPTO records.